







Models of Care

Here we share exemplar models of care from around the world. Many have transferable value to other contexts: 'Act Local Think Global'.

Find out more



Learning Zone

Here we include eresources to promote learning about paediatric musculoskeletal medicine and signpost to opportunities for training.

> Find out more



Global Networks

Here we signpost to networks and societies around the world. 'If you want to go far go it alone, if you want to go further, go together (African Proverb).

Find out more



Guidelines Reports and e-Newsletters

Here we signpost to outputs from our Task Force including our e-Newsletters. We also highlight useful resources around guidelines, policy and recommendations. Please share!

> Find out more

https://www.pmskglobal.com

Paediatric Global Musculoskeletal Task Force

- Founded in 2018 (led by Helen Foster): Global Alliance for Musculoskeletal Health (G-MUSC) & aligned to WHO strategy
 - Promoting investment in MSK health: 'a call to action'
 - Breadth of 'musculoskeletal' rheumatology, orthopaedics
 - Life course approach: many adult MSK morbidities have origins in childhood
- Joined forces PReS Global Task Force (led by Chris Scott) June 2019
- A Global Community with a shared vision to improve MSK health for all children
 - Promotion: Awareness of unmet need
 - Prevention: Obesity, road safety, accidents & injuries, promote healthy lifestyle (diet, exercise)
 - Treatment: Equitable access to 'right' care





Co-Chairs (2023)

- Chris Scott (paed rheum), Claudia Saad Magalhees (paed rheum)
- Helen Foster (Founder Co-Chair paed rheum),
- Matthew Dobbs (paed ortho), Carl Johan Tiderius (paed ortho)

Links with multiple associations & networks

- Rheumatology, orthopaedics, family groups & charities
- PReS, APLAR, PAFLAR, PANLAR, WOC, WORD-Day
- WHO Essential Medicines List, MSK Rehabilitation guidelines

Open global community, social media, e-Newsletters

- Twitter LinkedIn FaceBook
- Website: https://www.pmskglobal.com
- e-Newsletters disseminated via PReS and available https://www.pmskglobal.com/guidelines-reports-e-newsletters/
- Regional networks (e.g APLAR SIG, PAFLAR, PANLAR, ANZPRG, ArLAR, PReS)
- E-Newsletter contributions are very welcome!






Chris Scott (South Africa)



Helen Foster (UK)





Matt Dobbs (US)



Carl Johan Tiderius (Sweden)



Global Task Force and PMM Editorial Board meeting Prague 2022 First 'face to face' since 2019

'Working better together'

- Networking & information sharing hub
- Inspiring & supporting
- Addressing challenges with real action
- Advocating & giving a voice



"If you want to go fast, go alone.

If you want to go far, go together" - African

proverb



Global Task Force Steering Committee with members from around the world (rheumatology, orthopaedics, allied health, parent advocates)

https://www.pmskglobal.com/about-us/



Contents lists available at ScienceDirect

Best Practice & Research Clinical Rheumatology

journal homepage: www.elsevierhealth.com/berh



https://doi.org/10.1016/j.berh.2020.101566

Improving musculoskeletal health for children and young people — A 'call to action'

Helen E. Foster ^{a, *}, Christiaan Scott ^b, Carl J. Tiderius ^c, Matthew B. Dobbs ^d, Members of the Paediatric Global Musculoskeletal Task Force

Foster et al. Pediatric Rheumatology (2020) 18:60 https://doi.org/10.1186/s12969-020-00451-8

Pediatric Rheumatology


COMMENTARY


The paediatric global musculoskeletal task force - 'towards better MSK health for all'


Check for updates

Open Access

Helen E. Foster^{1*}, Christiaan Scott², Carl J. Tiderius³ and Matthew B. Dobbs⁴








Examples of our work and contributions

- WHO EML (Joint diseases) revision (submitted 2022)
- WORD day
- APLAR and PAFLAR Webinar series
- PMM Editorial Board and pGALS dissemination
- pGALS translations
- Australian Parliamentary Inquiry
- E-Newsletters
- Juvenile Arthritis Early Referral Tool
- Clinical Guidelines (Less resourced countries)
- International Meetings and Presentations

Awareness













Smith et al. Pediatric Rheumatology (2020) 18:71 https://doi.org/10.1186/s12969-020-00465-2

Pediatric Rheumatology

COMMENTARY

Open Access

Establishing an international awareness day for paediatric rheumatic diseases: reflections from the inaugural World Young Rheumatic Diseases (WORD) Day 2019

Eve M. D. Smith ^{1,2,3}, Sammy Ainsworth ^{4,5}, Michael W. Beresford ^{1,2,3,5}, Veerle Buys ^{4,6,7}, Wendy Costello ^{4,8}, Yona Egert ^{4,9}, Helen E. Foster ^{10,11,12}, Lovro Lamot ^{2,13,14}, Berent J. Prakken ^{2,15}, Christiaan Scott ^{11,16} and Simon R. Stones ^{4,17,18}






WED, 17 MAR-18 MAR
WORD Day 2021
Online event

Paediatric Musculoskeletal Matters Portfolio

Updated Expanded Version Launched Sept 2022 with >70 global

partners contributing content

Resources free & open to all for teaching and learning







www.pmmonline.org

Many pGALS translations and v-pGALS for telemedicine



Interactive e-modules and pGALS graphic animation all available on PMM




pGALS Translations

- 23 (so far) developed with many global partners
- V-pGALS for telehealth
- All free, openly available on pGALS App &

https://www.pmskglobal.com/learning-zone/
https://www.pmmonline.org/doctor/clinical-assessment/examination/

- If you want help add further languages
- please do get in touch with the PMM team
 - pmmonline.org@gmail.com






Regular e-Newsletters with contributions from around the world



By 2050 2 out of every 5 children will live in Africa

World Population


Source: UN




Disease burden vs. health expenditure per capita, 1995 to 2014




Total disease burden from all causes, measured as the number of Disability-Adjusted Life Years (DALYs) per 100,000 individuals, versus health expenditure per capita (measured in US\$).



Science Papers Published 2016





Beth D Harper, ⁹ 1 Waceke Nganga, ² Robert Armstrong, ³ Kevin D Forsyth, ⁴ Hazen P Ham, ⁵ William J Keenan, ⁶ Christiana M Russ ¹

international survey to understand the

Where are the paediatricians? An

global paediatric workforce

ВМЈ

Open

Paediatrics

*Data Source: UNICEF Country Statistics

Figure 1 Pediatrician density per 100 000 children <18 years old*.






Figure 2 Type of provider seen for primary care.





WORLDS CHILDREN

WORLDS PAEDIATRIC RHEUMATOLOGISTS

Scott, Sawhney, Lewandowski 2020

Pediatric Rheumatology


RESEARCH ARTICLE

Open Access

Global prevalence estimates of three chronic musculoskeletal conditions: club foot, juvenile idiopathic arthritis and juvenile systemic lupus erythematosus



Mona Dave, Judith Rankin, Mark Pearce and Helen E. Foster*



Estimated global prevalence of clubfoot, JIA and juvenile SLE in 2017:



2.95 million

Children and young people. Disease prevalence was greatest in South Asia, followed by Africa, the Americas, Europe and Oceania.



Nearly 3 million children and young people around the world have clubfoot, JIA or juvenile SLE, according to data.






Fig. 1 Total estimated number of cases of dubfoot, JIA and JSLE across all countries included in analysis, 2017. The totals here are the sums of individual country data and will therefore be slightly different to the total when calculated by summing region data or sub-region data in subsequent figures due to rounding error

Estimated number of children with a musculoskeletal condition in 2017 by UN region



Estimated number of children with one of 3 exemplar conditions in 2017 by UN region



Helen Foster

Large numbers of children with Modificanditions in countries with higher total populations and higher % of children (1, 1, 2007, 27%)



Contents lists available at ScienceDirect

Best Practice & Research Clinical Rheumatology

journal homepage: www.elsevierhealth.com/berh



https://doi.org/10.1016/j.berh.2020.101566

Improving musculoskeletal health for children and young people — A 'call to action'

Helen E. Foster ^{a, *}, Christiaan Scott ^b, Carl J. Tiderius ^c, Matthew B. Dobbs ^d, Members of the Paediatric Global Musculoskeletal Task Force

Foster et al. Pediatric Rheumatology (2020) 18:60 https://doi.org/10.1186/s12969-020-00451-8

Pediatric Rheumatology


COMMENTARY

Open Access

The paediatric global musculoskeletal task force - 'towards better MSK health for all'



Helen E. Foster^{1*}, Christiaan Scott², Carl J. Tiderius³ and Matthew B. Dobbs⁴




JAMLESS: Juvenile Arthrtitis management in Less Resourced Countries










Steering group of international PR

Scott et al Clin Rheumatol 2013









JAMless South East Asia in progress (2023)

'AKLIAMENT OF THE COMMONWEALTH OF AUSTRALIA

Inquiry into childhood rheumatidiseases: Interim report

House of Representatives Standing Committee on Health, Aged Care and Sport



State	Population of children 0-19 years	Required paediatric rheumatologist staffing (EFT)	Actual public paediatric rheumatologist staffing (EFT)	Percentage of required public EFT
New South Wales	1,975,852	9.9	1.25	12.6 per cent
Victoria	1,589,497	7.9	3.94	49.9 per cent
Queensland	1,317,012	6.6	1.6	24.2 per cent
South Australia	411,722	2.1	1.3	61.9 per cent
Western Australia	672,432	3.4	1.8	52.9 per cent
Tasmania	125,041	0.6	0	0.0 per cent
Northern Territory	67,677	0.3	0	0.0 per cent
Australian Capital Territory	106,455	0.5	0	0.0 per cent
National	6,265,688	31.3	9.89	31.6 per cent

Source: Australian Paediatric Rheumatology Group, Submission 70, p. 15

Medication	N (%)	Medication	N (%)
Methotrexate	173 (100%)	TNF Inhibitor	168 (97%)
 Methotrexate 	– 143 (83%)	Adalimumab	– 152 (88%)
 Methotrexate 	– 147 (85%)	Etanercept	- 115 (66%)
(Subcutaneous)		– Infliximab	- 77 (45%)
Sulphasalazine	55 (32%)	IL6 Inhibitor	151 (87%)
		 Tocilizumab (Intravenous) 	– 121 (70%)
		Tocilizumab (Subcutaneous)	- 90 (52%)
Hydroxychloroquine	77 (45%)	IL1 Inhibitor	123 (71%)
		– Anakinra	– 120 (69%)
		Rilonacept	- 4 (2%)
		Canakinumab	– 31 (18%)
Intra-articular Steroids	157 (91%)	Abatacept	39 (23%)
 Triamcinolone Hexacetonide (TH) 	- 134 (77%)		
Triamcinolone Acetonide	– 35 (30%)		
Methylprednisolone Acetate	- 32 (19%)		
Prednisolone	150 (87%)	Rituximab	75 (43%)

Foster, Slamang, Scott, Smith

Review of the management of Juvenile Idiopathic Arthritis

A narrative review of the management of juvenile idiopathic arthritis

This report aims to contextualise the medicines used in the different subtypes of JIA and provide the rationale for current therapeutic strategies.

Executive summary The Selection and Use of Essential Medicines 2021

Report of the 23rd WHO Expert Committee on the Selection and Use of Essential Medicines

Virtual meeting, 21 June–2 July 2021



2022 PReS Appoints Global Health Research Fellow to follow up guidelines submission with the WHO: Dr Waheba Slamang (South Africa)